Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Hysek, Cédric M ^a   Simmler, Linda D ^a   Nicola, Valentina G ^a   Vischer, Nerina ^a   Donzelli, Massimiliano ^a   Krähenbühl, Stephan ^a   Grouzmann, Eric ^b   Huwyler, Jörg ^a   Hoener, Marius C ^c   Liechti, Matthias E ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CITALOPRAM; DULOXETINE; INDATRALINE; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN; SEROTONIN TRANSPORTER; 3,4 METHYLENEDIOXYAMPHETAMINE; ADRENERGIC RECEPTOR; THIOPHENE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORADRENALIN RELEASE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; LABORATORY; METABOLISM; PLACEBO EFFECT; SECRETION; TRANSPORT AT THE CELLULAR LEVEL;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; BIOLOGICAL TRANSPORT; FEMALE; HUMANS; LABORATORIES; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; PLACEBO EFFECT; RECEPTORS, ADRENERGIC; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THIOPHENES;

EID: 84860539094     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036476     Document Type: Article

References (50)

1. Rudnick G, Wall SC, (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89: 1817-1821.
2. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, et al. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
3. Verrico CD, Miller GM, Madras BK, (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189: 489-503.
4. Wall SC, Gu H, Rudnick G, (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47: 544-550.
5. Rothman RB, Partilla JS, Baumann MH, Dersch CM, Carroll FI, et al. (2000) Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 35: 222-227.
6. Rothman RB, Baumann MH, Blough BE, Jacobson AE, Rice KC, et al. (2010) Evidence for noncompetitive modulation of substrate-induced serotonin release. Synapse 64: 862-869.
7. Liechti ME, Baumann C, Gamma A, Vollenweider FX, (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
8. Tancer M, Johanson CE, (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189: 565-573.
9. Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, et al. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323: 954-962.
10. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, et al. (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmacol Ther 90: 246-255.
11. Sofuoglu M, Poling J, Hill K, Kosten T, (2009) Atomoxetine attenuates dextroamphetamine effects in humans. Am J Drug Alcohol Abuse 35: 412-416.
12. Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, et al. (2012) Effects of the α2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340: 286-294.
13. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, et al. (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880.
14. Wong DT, (1998) Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Expert Opin Investig Drugs 7: 1691-1699.
15. Segura M, Farre M, Pichini S, Peiro AM, Roset PN, et al. (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44: 649-660.
16. Knadler MP, Lobo E, Chappell J, Bergstrom R, (2011) Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 50: 281-294.
17. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB, (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159-163.
18. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M, (1997) SKID-I: Strukturiertes Klinisches Interview für DSM-IV. Göttingen Hogrefe-Verlag.
19. Derogatis LR, Rickels K, Rock AF, (1976) The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 128: 280-289.
20. Schmitz N, Hartkamp N, Kiuse J, Franke GH, Reister G, et al. (2000) The Symptom Check-List-90-R (SCL-90-R): a German validation study. Qual Life Res 9: 185-193.
21. Janke W, Debus G, (1978) Die Eigenschaftswörterliste. Göttingen, Germany Hogrefe.
22. Dittrich A, (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31 S2: 80-84.
23. Studerus E, Gamma A, Vollenweider FX, (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5: e12412.
24. Cami J, Farre M, Mas M, Roset PN, Poudevida S, et al. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466.
25. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, et al. (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28: 432-440.
26. Zerssen DV, (1976) Die Beschwerden-Liste. Münchener Informationssystem. München Psychis.
27. Simmler LD, Hysek CM, Liechti ME, (2011) Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab 96: 2844-2850.
28. Tatsumi M, Groshan K, Blakely RD, Richelson E, (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258.
29. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
30. Torok M, Huwyler J, Drewe J, Gutmann H, Fricker G, (1998) Transport of the β-lactam antibiotic benzylpenicillin and the dipeptide glycylsarcosine by brain capillary endothelial cells in vitro. Drug Metab Dispos 26: 1144-1148.
31. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E, (1993) Psychological effects of MDE in normal subjects: are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8: 171-176.
32. Bedi G, Hyman D, de Wit H, (2010) Is ecstasy an "empathogen"? Effects of±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 68: 1134-1140.
33. Van Dyke C, Jatlow P, Ungerer J, Barash PG, Byck R, (1978) Oral cocaine: plasma concentrations and central effects. Science 200: 211-213.
34. Pifl C, Nagy G, Berenyi S, Kattinger A, Reither H, et al. (2005) Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. J Pharmacol Exp Ther 314: 346-354.
35. Han DD, Gu HH, (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 6.
36. Rothman RB, Baumann MH, (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23-40.
37. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, et al. (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 102: 3495-3500.
38. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, et al. (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A 97: 6850-6855.
39. Robertson SD, Matthies HJ, Galli A, (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39: 73-80.
40. Matthies HJ, Moore JL, Saunders C, Matthies DS, Lapierre LA, et al. (2010) Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking. J Neurosci 30: 7863-7877.
41. Field JR, Henry LK, Blakely RD, (2010) Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylenedioxymethamphetamine. J Biol Chem 285: 11270-11280.
42. Thompson BJ, Jessen T, Henry LK, Field JR, Gamble KL, et al. (2011) Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter. Proc Natl Acad Sci U S A 108: 3785-3790.
43. Baumann MH, Clark RD, Rothman RB, (2008) Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav 90: 208-217.
44. Verrico CD, Lynch L, Fahey MA, Fryer AK, Miller GM, et al. (2008) MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol 22: 187-202.
45. Liechti ME, Vollenweider FX, (2000) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10: 289-295.
46. Zhao RK, Cheng G, Tang J, Song J, Peng WX, (2009) Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Clin Ther 31: 1022-1036.
47. Hondebrink L, Meulenbelt J, Meijer M, van den Berg M, Westerink RH, (2011) High concentrations of MDMA ("ecstasy") and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells. Neuropharmacology 61: 202-208.
48. Gudelsky GA, Yamamoto BK, Nash JF, (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 264: 325-330.
49. Gudelsky GA, Nash JF, (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66: 243-249.
50. Gould GG, Javors MA, Frazer A, (2007) Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry 61: 210-215.